Keywords
Endometriosis
Goserelin
Menorrhagia
Quality of life
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Goserelin reduces the estrogen levels and is approved for several hormonally sensitive benign disorders. There are few data about the quality of life of women using goserelin for benign disorders. The purpose of this article is to objectively assess the quality of life of these women. Methods: We searched from electronic databases as PubMed, Scielo, LILACS, among others. The inclusion criteria were RCTs which evaluated using validated questionnaires the quality of life of women with benign gynecological disorders treated with goserelin. Results: The five RCTs demonstrated improvement in quality of life after goserelin compared to the baseline. It was evidenced a temporary effect of the goserelin. Goserelin by itself or associated with another therapy improves the quality of life when compared to the baseline. Hot flushes are not an expressive cause of patient noncompliance. The temporary effect of goserelin is in accordance with literature. Final considerations: This systematic review suggests that goserelin is an effective treatment for benign gynecological disorders, but more studies are necessary to embark therapy choice.
References
AL-AZEMI M, et al. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG, 2009; 116 (12): 1646-1656.
BIBEROGLU KO and BEHRMAN SJ. Dosage aspects of danazol therapy in endometriosis: short term and long term effectiveness. Am J Obstet Gynecol, 1981; 139(6): 645-654.
BRAZIER JE, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ, 1992; 305(6846): 160-164.
BROWN J and FARQUHAR C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev, 2014, 2014(3).
COOPER KG, et al. A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. British Journal of Obstetrics and Gynaecology,1997, 104 (12):1360-1366.
COOPER KG, et al. Comparison of microwave endometrial ablation and transcerv icalresection of the endometrium for treatment of heavy menstru al loss: a randomised trial. The lancet, 1999; 354(9193): 1859-63.
GARRATT AM, et al. Measuring sexual functioning in premenopausal women. Br J Obstet Gynaecol, 1995, 102(4): 311-316
JONES G, et al. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstet Gynecol, 2001; 98(2): 258-64.
JONES GL, et al. Health-related quality of life measurement in women with common benign gynecologic conditions: A systematic review. American Journal of Obstetrics and Gynecology, 2002; 187(2): 501–511.
LABEL. Zoladex. Available in: https://www.farmadelivery.com.br/media/upload/pdf/BULAS/ASTRAZENECA/Zoladex-e-Zoladex-Depot.pdf. Accessed in: August 29, 2022.
MELZACK R. The Short-form McGill Pain Questionnaire. Pain, 1987; 30(2): 191–197.
MILLER RM and FRANK RA. ZoladexR (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. British Journal Journal of Obstetrics and Gynaecology, 1992, 99(7): 37–41.
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012. Available in: https://www.ncbi.nlm.nih.gov/books/NBK548740. Accessed in: August 29, 2022.
PERRY CM and BROGDEN RN. Goserelin. Drugs, 1996; 51(2): 319–346.
SANGKOMKAMHANG US, et al. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy). Cochrane Database of Systematic Reviews, 2020; 11(11).
SOYSAL ME, et al. A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. Human Reproduction, 2001, 16(5): 931–939.
SOYSAL S. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Human Reproduction, 2004; 19(1):160-167.
UNITED KINGDOM. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley & Sons. 2017. Disponível em: https://training.cochrane.org/handbook. Accessed in: August 29, 2022.
VON KM, et al. Grading the severity of chronic pain. Pain, 1992; 50(2):133–149.
ZIGMOND AS and SNAITH RP. The hospital anxiety and depression scale. Acta Psychiatr Scand., 1983; 67(6): 361-70.